GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » Cost of Goods Sold

ClearPoint Neuro (ClearPoint Neuro) Cost of Goods Sold : $11.22 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro Cost of Goods Sold?

ClearPoint Neuro's cost of goods sold for the three months ended in Mar. 2024 was $3.11 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2024 was $11.22 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ClearPoint Neuro's Gross Margin % for the three months ended in Mar. 2024 was 59.24%.

Cost of Goods Sold is also directly linked to Inventory Turnover. ClearPoint Neuro's Inventory Turnover for the three months ended in Mar. 2024 was 0.39.


ClearPoint Neuro Cost of Goods Sold Historical Data

The historical data trend for ClearPoint Neuro's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro Cost of Goods Sold Chart

ClearPoint Neuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.94 3.71 5.18 7.02 10.34

ClearPoint Neuro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.23 2.82 2.49 2.80 3.11

ClearPoint Neuro Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ClearPoint Neuro  (NAS:CLPT) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ClearPoint Neuro's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(7.639 - 3.114) / 7.639
=59.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

ClearPoint Neuro's Inventory Turnover for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


ClearPoint Neuro Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


ClearPoint Neuro (ClearPoint Neuro) Business Description

Traded in Other Exchanges
N/A
Address
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.
Executives
Lynnette C Fallon director 108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau director 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra officer: Chief Operating Officer 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett director, officer: CEO and President C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall officer: GM, Biologics & Drug Delivery 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro officer: Vice President, Finance 5 MUSICK, IRVINE CA 92618
Harold A Hurwitz officer: Chief Financial Officer
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R director C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards director ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc. 10 percent owner 75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners officer: Vice President, Marketing ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103

ClearPoint Neuro (ClearPoint Neuro) Headlines

From GuruFocus

ClearPoint Neuro to Announce Third Quarter 2022 Results November 8, 2022

By Value_Insider Value_Insider 10-26-2022

ClearPoint Neuro Announces Receipt of MDSAP Certification

By GuruFocusNews GuruFocusNews 06-22-2022

ClearPoint Neuro Announces Receipt of MDSAP Certification

By PurpleRose PurpleRose 07-12-2022